The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 26, 2025
Filed:
Nov. 04, 2016
Applicant:
Imperial College Innovations Limited, London, GB;
Inventor:
Mark Isalan, London, GB;
Assignee:
IMPERIAL COLLEGE INNOVATIONS LIMITED, London, GB;
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 47/64 (2017.01); A61P 25/14 (2006.01); A61P 25/28 (2006.01); C07K 7/04 (2006.01); C07K 14/00 (2006.01); C07K 14/47 (2006.01); C12N 7/00 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01); C12N 15/864 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 47/64 (2017.08); A61K 48/0025 (2013.01); A61K 48/0075 (2013.01); A61P 25/14 (2018.01); A61P 25/28 (2018.01); C07K 14/4702 (2013.01); C12N 7/00 (2013.01); C12N 15/113 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01);
Abstract
Disclosed herein are novel nucleic acid molecules which encode novel polypeptides for use in treating polyglutamine diseases such as Huntington's disease. The polypeptides of the invention exhibit reduced immunotoxicity in vivo and may have utility in sustained (mid- or long-term) expression in vivo. Also disclosed are methods for the treatment of polyglutamine diseases, such as Huntington's disease and the use of nucleic acids and polypeptides of the invention in medical therapy. Gene therapy methods and compositions, such as AAV vectors for use in gene therapy methods are also disclosed.